ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 918 USD | +0.38% |
|
+0.40% | +57.48% |
| Jul. 08 | Health Care Flat Amid Deal Activity -- Health Care Roundup | DJ |
| Jul. 08 | S&P 500, Nasdaq Extend Record Closing Runs | MT |
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
2024-08-08
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
918
USD
Average target price
870.3
USD
Spread / Average Target
-5.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +57.48% | 823B | |
| -7.18% | 353B | |
| +15.37% | 320B | |
| +7.45% | 295B | |
| +13.62% | 239B | |
| +14.55% | 220B | |
| -0.33% | 219B | |
| +8.14% | 167B | |
| -2.99% | 159B | |
| +2.61% | 123B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Goldman Sachs Adjusts Price Target on Eli Lilly to $785 From $740
